Short answer: the real difference between 510(k), De Novo, and PMA is not speed. It is risk tolerance.

Each pathway reflects how much uncertainty the U.S. Food and Drug Administration is willing to accept—and how much evidence they require to reduce that uncertainty.

If you only compare timelines, you miss the point. The pathway determines how much proof you must generate to justify patient safety.

Let’s break it down clearly.

The Real Comparison: Risk Tolerance
1. 510(k): Lowest Regulatory Uncertainty

The 510(k) pathway is built on one core concept: substantial equivalence.

FDA asks:

Is there an existing legally marketed device (predicate)?

Does your device have the same intended use?

Are technological differences minimal and not introducing new risks?

If the answer is yes, FDA does not require you to prove safety and effectiveness from scratch. You only need to demonstrate that your device is no riskier than what is already on the market.

Risk Tolerance Profile:

Low-to-moderate risk

Established regulatory history

Controlled technological differences

Evidence Expectation:

Bench testing

Performance validation

Possibly limited clinical data

FDA is tolerating some uncertainty—but only because precedent exists.

2. De Novo: Moderate Uncertainty, Managed Risk

De Novo applies when:

No predicate device exists

The device is novel

The risk level is still low-to-moderate

Here, FDA is willing to accept innovation—but only if risks can be clearly identified and mitigated.

Risk Tolerance Profile:

Moderate uncertainty

First-of-a-kind technologies

Risk controls must be clearly defined

Evidence Expectation:

More extensive bench testing

Often clinical evidence

Strong risk management documentation

FDA is not relying on precedent here. They are relying on your evidence.

3. PMA: Minimal Uncertainty Tolerance

Premarket Approval (PMA) is required when:

The device is high risk

It sustains or supports life

It is implanted long-term

Failure could cause serious harm

Here, FDA has very low tolerance for uncertainty.

Risk Tolerance Profile:

High patient impact

Significant harm potential

Limited room for ambiguity

Evidence Expectation:

Extensive preclinical testing

Well-controlled clinical trials

Comprehensive benefit-risk analysis

FDA requires strong, independent evidence of safety and effectiveness. Not similarity. Not plausibility. Proof.

What This Means Strategically

Choosing a pathway is choosing how much uncertainty your company must eliminate.

510(k): Reduce uncertainty by showing similarity

De Novo: Reduce uncertainty by demonstrating controlled innovation

PMA: Eliminate uncertainty through rigorous clinical proof

The higher the risk tolerance required, the more capital and time you must invest.

This is not about moving fast.
It is about aligning your device risk with the correct evidence burden.

The Most Common Founder Mistake

Many teams ask:

“Which pathway is fastest?”

The better question is:

“Which pathway reflects the true risk profile of this device?”

If the device risk is underestimated, the pathway will eventually shift.
And pathway shifts are expensive.

Where Kandih Comes In

This is where Kandih Group supports teams with structured comparative pathway analysis.

Kandih’s process includes:

Defining and pressure-testing intended use

Conducting classification and regulatory code assessments

Evaluating predicate strength and technological differences

Identifying hidden risk escalators

Comparing viable pathways side-by-side

Modeling cost, timeline, and capital exposure under each pathway

Instead of defaulting to the “fastest” route, teams make evidence-based pathway decisions aligned with FDA risk logic.

That protects:

Development timelines

Investor confidence

Capital allocation

Long-term strategy

Bottom Line

The difference between 510(k), De Novo, and PMA is not just procedural.

It is about how much uncertainty FDA is willing to accept—and how much proof you must provide.

Speed is a byproduct.
Risk tolerance is the driver.

Understanding that difference early prevents expensive pivots later.

References

FDA – Premarket Notification 510(k)
https://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k

FDA – De Novo Classification Process
https://www.fda.gov/medical-devices/premarket-submissions/de-novo-classification-request

FDA – Premarket Approval (PMA)
https://www.fda.gov/medical-devices/premarket-submissions/premarket-approval-pma

FDA – Classify Your Medical Device
https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device